The Mundipharma network of independent associated companies says European regulators have approved use of Pelmeg, a biosimilar of Amgen’s white blood cell booster Neulasta. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/eu_oks_mundipharmas_neulasta_biosimilar_1265039Sunovion’s application to market dasotraline for the treatment of attention-deficit hyperactivity disorder (ADHD) has been rejected by US regulators. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/fda_rejects_sunovions_adhd_drug_1251093GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of
by Selina McKee
www.pharmatimes.com/news/gw_completes_epidiolex_submission_1209905London, UK-based Arix Bioscience has entered into a strategic agreement with French drugmaker Ipsen to develop and commercialise innovative therapies. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/arix_ties_with_ipsen_1223364Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_ups_its_offer_for_shire_1232830AstraZeneca has completed its $2.7-billion acquisition of ZS Pharma, bolstering its cardiovascular and metabolic disease portfolio. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_completes_acquisition_of_zs_pharma_972294AstraZeneca has bumped up its stake in US biotech Moderna, which is pioneering the development of a new class of drugs made of messenger RNA, to nine percent. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_ups_stake_in_moderna_1095937Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi,_msd_to_dismantle_vaccines_jv_1020306Astellas’ experimental acute myeloid leukaemia drug gilteritinib has been awarded orphan drug designation by the European Commission. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/astellas_bags_orphan_drug_status_for_aml_drug_1218291AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_buys_ionis_nash_candidate_1231077
